Astrazeneca Ord Shs AZNCF

Healthcare

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

OTCPK:AZNCF - Post by User

Astrazeneca Ord Shs

Bullboard Posts

Post by bc4uon Jan 31, 2013 2:31am

713 Views

Post# 20915756

AstraZeneca PLC FOURTH QUARTER AND FULL YEAR RESUL

AstraZeneca PLC FOURTH QUARTER AND FULL YEAR RESULTS 2012

London, 31 January 2013
Financial performance for the full year reflects the loss of exclusivity on several brands. At constant
exchange rates (CER), revenue declined by 15 percent and Core EPS declined by 9 percent.
Brilinta/Brilique, Symbicort, Faslodex, Onglyza and Iressa continue to grow, while diabetes alliance
franchise is strengthened by the inclusion of Amylin portfolio and the approval of Forxiga in Europe.
The Company will hold a Capital Markets Day on 21 March 2013 to provide a strategy update.
Revenue for the full year was $27,973 million, down 15 percent at CER.
-Loss of exclusivity on several brands and the disposals of Astra Tech and Aptium were the key drivers of
the revenue decline.
-Symbicort, Faslodex, Onglyza, Iressa, Brilinta/Brilique and Seroquel XR combined to deliver $600 million
of CER revenue growth for the full year.
Core EPS was $6.41 for the full year, a 9 percent decline at CER.
-Core EPS in 2012 benefited by $470 million ($0.37) from two separate tax related matters during the
year. Proceeds from the sale of Nexium OTC rights contributed $0.16 to Core EPS.
Reported EPS for the full year was down 29 percent at CER to $4.99. The decline reflects the $1.08 per
share benefit in 2011 from the sale of Astra Tech and higher restructuring costs in 2012.
Revenue in the fourth quarter was down 15 percent; Core EPS was up 1 percent as a result of lower
operating costs (including significantly lower intangible impairment costs in R&D) and a favourable
$230 million adjustment to deferred tax balances following substantive enactment of a reduction in the
Swedish corporation tax rate.
The Board has declared a second interim dividend of $1.90 per share, bringing the dividend for the full
year to $2.80, consistent with the progressive dividend policy.
The Company expects a mid-to-high single digit percentage decline in revenue at CER for 2013. With
Core operating costs expected to be slightly higher than 2012 at CER, Core EPS will decline
significantly more than revenue.